Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 3, 2006, Pages 210-216

  Badros, Ashraf ^a   Goloubeva, Olga ^a   Fenton, Robert ^a   Rapoport, Aaron P ^a   Akpek, Gorgun ^a   Harris, Carolynn ^a   Ruehle, Kathleen ^a   Westphal, Sandra ^a   Meisenberg, Barry ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Cisplatin; Cyclophosphamide; Doxorubicin; Engraftment

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ETOPOSIDE; FAMCICLOVIR; FLUCONAZOLE; GATIFLOXACIN; INSULIN; MELPHALAN; PHENYTOIN; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFECTION; LEUKAPHERESIS; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLASMACYTOMA; RELAPSE; SEIZURE; STEM CELL MOBILIZATION; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; WEAKNESS;

EID: 34248218687     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.061     Document Type: Article

References (36)

1. Anderson KC, Pazdur R, Farrell AT. Development of effective new treatments for multiple myeloma. J Clin Oncol 2005; 23:7207-7211.
2. Gertz, MA, Lacy MQ, Dispenzieri A, et al. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther 2006; 6:343-360.
3. Harousseau JL. Stem cell transplantation in multiple myeloma (0, 1, or 2). Curr Opin Oncol 2005; 17:93-98.
4. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5:417-421.
5. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating aritimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101:1530-1534.
6. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5:18.
7. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
8. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498.
9. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-172.
10. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783.
11. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/ boriezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-762.
12. Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2005; 1-11.
13. Ma MH, Yang HH, Porter K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9:1136-1144.
14. Adjei AA. Sequencing bortezomib with chemotherapy and targeted agents. Clin Lung Cancer 2005; 7(suppl 2):S56-S58.
15. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myetoma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101:2377-2380.
16. Yang HH, Vescio R, Schenkein D, et al. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, Velcade and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 2003; 4:119-122.
17. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105:3058-3065.
18. Chanan-Khan A, Miller KC. Velcade, Doxil and thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leuk Lymphoma 2005; 46:1103-1104.
19. Hollmig K, Stover J, Talamo G, et al. Bortezomib (Velcade™) + Adriamycin™ + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). Blood 2004; 104:659a (Abstract #2399).
20. Barlogie B, Hollmig K, Zangari M, et al. Total therapy 3 (TT 3) for newly diagnosed myeloma, incorporating velcade into remission induction with DT PACE: early results regarding efficacy, PBSC mobilization and toxicities. Blood 2004; 104:156a (Abstract #538).
21. Boccadoro, M, Blade J, Attal M, et al. The future role of thalidomide in multiple myeloma. Acta Haematol 2005; 11 4(suppl 1): 18-22.
22. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 2004; 22:3212-3214.
23. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myelorna. J Clin Oncol 2003; 21:2732-2739.
24. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-436.
25. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89:826-831.
26. Ghobrial IM, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003; 32:587-592.
27. Kumar S, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. Nat Clin Pract Oncol 2005; 2:262-270.
28. Carley L, Tai YT, Chauhan D, et al. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat 2005; 8:205-218.
29. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma. treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-1123.
30. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352-1361.
31. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:893-898.
32. Jimenez-Zepeda VH, Dominguez-Martinez VJ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? Eur J Haematol 2006; 77:239-244.
33. Cavo M, Zamagni E, Tosi P. et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106:35-39.
34. Rajkurnar SY, Fonseca R, Dispenzieri A, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26:979-983.
35. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-2502.
36. Peles S, Fisher NM, Devine SM, et al. Bortezomib (Velcade) when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV). Blood 2005; 106:905a (Abstract #3237).